CSBR (Champions Oncology) Tariff Resilience Score: 7/10 (As of Jul. 01, 2026)


CSBR Champions Oncology Inc CSBR
64 GF Score
Price $6.05
GF Value $6.63
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology Tariff Resilience Score?

Champions Oncology CSBR -4.95% 64 Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.63 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,374 Biotechnology companies, Champions Oncology ranks better than 90.39% on this metric.

Champions Oncology has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Champions Oncology has Biotech company with some international exposure. Resilient due to niche market, potential for alternative suppliers, and strong R&D focus.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Champions Oncology might have Highly Resilient.

Champions Oncology  (NAS:CSBR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Champions Oncology Tariff Resilience Score Related Terms

CSBR vs SEER, RLYB, FBIO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Champions Oncology's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Champions Oncology Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Tariff Resilience Score falls into.


CSBR
64GF Score
Champions Oncology Inc CSBR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Champions Oncology (CSBR) has a Tariff Resilience Score of 7 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Champions Oncology ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Champions Oncology's Tariff Resilience Score too high?
Champions Oncology's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Champions Oncology's value of 7 is 75% above this industry median. Based on the distribution chart, Champions Oncology ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Tariff Resilience Score compare to SEER and RLYB?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #132 out of 1374 companies for Tariff Resilience Score. This places Champions Oncology in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Champions Oncology's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.63, compared to a current price of $6.05 — trading 8.8% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $6.05 is trading 8.8% below its estimated GF Value™ of $6.63. GuruFocus considers Champions Oncology to be Fairly Valued.

Key valuation signals for CSBR:

  • Tariff Resilience Score: 7
  • GF Value™: $6.63 vs. price of $6.05 (8.8% below fair value)
  • GF Score™: 64/100 with 2 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1374)

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score

Get the complete analysis for CSBR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.05
Price
$6.63
GF Value